The CBX8 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt chromobox homolog 8 (CBX8) function. This polyclonal format provides a genetically heterogeneous pool of edited cells, enabling interrogation of CBX8 loss-of-function effects across diverse editing outcomes within a defined hepatocellular carcinoma background. The knockout has been generated via target-gene disruption without isolation of single-cell clones, offering a robust and population-level model for functional genomics studies.
SK-HEP-1 is a human hepatic adenocarcinoma cell line originally derived from ascitic fluid of a patient with liver adenocarcinoma. Although initially misclassified as endothelial, this line has been confirmed as epithelial in origin and is widely employed in hepatocellular carcinoma research. The cells maintain key characteristics of liver cancer, including epithelial morphology and malignant growth properties, making them a physiologically relevant host for investigating epigenetic regulators such as CBX8 in hepatocarcinogenesis.
CBX8 is a core component of the Polycomb repressive complex 1 (PRC1), where it functions as a reader of trimethylated lysine 27 on histone H3 (H3K27me3). Through direct interactions with BMI1 and the catalytic RING1A/RING1B (RNF2) subunits, as well as PHC proteins, CBX8 contributes to stable chromatin association and transcriptional silencing of critical loci. Its activity is regulated upstream by MYC and the Wnt/??-catenin pathway, and it represses key targets including the INK4A/ARF locus (CDKN2A) and HOX gene clusters. Disruption of CBX8 abrogates PRC1 chromatin anchoring, leading to derepression of these tumor suppressors and developmental regulators.
In the SK-HEP-1 liver cancer context, CBX8 knockout provides a powerful model to dissect PRC1-mediated gene silencing in hepatocellular carcinoma. Loss of CBX8 is anticipated to relieve Polycomb-dependent repression of CDKN2A, potentially triggering senescence or apoptosis and impairing proliferation. This model enables functional interrogation of epigenetic vulnerabilities and facilitates exploration of synthetic lethal interactions or validation of CBX8 as a therapeutic target in hepatic malignancies, where aberrant PRC1 activity is frequently observed.
The CBX8 Knockout SK-HEP-1 Polyclonal Cells are suited for chromatin immunoprecipitation (ChIP-qPCR) to assess H3K27me3 occupancy, RT-qPCR and western blotting to quantify target derepression, and proliferation or apoptosis assays (MTT, Annexin V) for functional phenotyping. Flow cytometry enables cell cycle profiling, while RNA-seq supports transcriptome-wide analysis of CBX8-dependent regulation. These applications advance epigenetic research, drug target validation, and functional genomics in liver cancer. For further information, please contact Ascent Research.
